Using AI to personalize drug dosing for liver cancer treatment
AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma
This study is testing whether using artificial intelligence to personalize drug doses can help people with liver cancer get better treatment with fewer side effects.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 12 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Sponsor | University of Florida Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Gainesville, Florida) |
| Trial ID | NCT05669339 on ClinicalTrials.gov |
What this trial studies
This trial investigates the safety and efficacy of a combination of three drugs—sorafenib, sonidegib, and irinotecan—administered at individually optimized doses for patients with hepatocellular carcinoma. The study aims to establish safe dose ranges for these drugs while utilizing an artificial intelligence approach to personalize treatment based on patient-specific factors. By measuring plasma circulating tumor DNA and assessing toxicity, the trial seeks to maximize treatment effectiveness and minimize adverse effects. The goal is to improve clinical outcomes compared to standard care.
Who should consider this trial
Good fit: Ideal candidates include adults with advanced-stage hepatocellular carcinoma who are not eligible for curative surgical or locoregional therapies.
Not a fit: Patients with multiple active malignancies or those with a life expectancy of less than 12 weeks may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and safer treatment options for patients with hepatocellular carcinoma.
How similar studies have performed: While the use of AI in drug dosing is an emerging field, similar studies have shown promise in personalizing cancer treatment, suggesting potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults ≥ eighteen years of age * Biopsy proven advanced-stage hepatocellular carcinoma (HCC), as confirmed by pathological analysis; or confirmation of HCC from a LI-RADS 5 imaging score. * Not eligible for, or had disease progression after, surgical or locoregional therapies when these treatments are intended as sole, definitive therapy aimed at curing the disease, rather than as part of a combination therapy approach * Subjects must not have more than one active malignancy at the time of enrollment (Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen \[as determined by the treating physician and approved by the PI\] may be included). * Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less. * Child-Pugh liver function class A or B7 * Life expectancy of 12 weeks or more * At least one target lesion that could be measured in one dimension, according to the Response Evaluation Criteria in Solid Tumors (mRECIST). * Must have lab values consistent with the following: 1. Platelet count ≥ 60,000 2. Hemoglobin, ≥8.0 g/dL 3. INR ≤2.5 4. Albumin ≥2.5 g/dL 5. Total bilirubin, ≤5 mg/dL 6. ALT \& AST ≤5 times the upper limit of normal 7. Creatinine ≤ 2 times the upper limit of normal * Written informed consent obtained from the subject and the subject agrees to comply with all the study-related procedures. * Subjects of childbearing potential (SOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for at least 20 months after the last dose of study drug to minimize the risk of pregnancy. * Subjects with partners of child-bearing potential must agree to use physician-approved contraceptive methods (e.g., abstinence, condoms, vasectomy) throughout the study and should avoid conceiving children for 8 months following the last dose of study drug. Exclusion Criteria: * Subjects of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 20 months after the last dose of study drug. * Subjects who are pregnant or breastfeeding. * History of any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of protocol therapy or that might affect the interpretation of the results of the study or that puts the subject at high risk for treatment complications or protocol noncompliance, in the opinion of the treating physician. * Prisoners or subjects who are involuntarily incarcerated, or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness. * Inability to follow up with treatment center for up to 12 weeks after enrollment * Anticipated major surgery during the time of planned study * Homozygosity for UGT1A1\*28 via genotyping
Where this trial is running
Gainesville, Florida
- University of Florida — Gainesville, Florida, United States (Recruiting)
Study contacts
- Principal investigator: Ali Zarrinpar, MD, PhD — University of Florida
- Study coordinator: Jessica Ross
- Email: rossjd5@ufl.edu
- Phone: 352-273-5257
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.